Kurobe Pharmaceuticals
About:
Kurobe Pharmaceuticals is a developer of therapeutics for eye infections and corneal ulcers.
Description:
Kurobe, headquartered in Tampa, has licensed a product from a Japanese company to treat methicillin-resistant staphylococcus aureus (MRSA) in the eye, said Barry Butler, president and CEO. Kurobe is one of several companies under the umbrella of Point Guard Partners LLC, established by former management executives at Sirion Holdings Inc. after that Tampa-based biopharma firm was sold in 2010. Butler, who was CEO of Sirion, is managing partner of Point Guard.
Total Funding Amount:
$5M
Headquarters Location:
Tampa, Florida, United States
Founded Date:
2012-01-01
Founders:
Number of Employees:
1-10
Last Funding Date:
2013-06-04
IPO Status:
Private
Industries:
© 2025 bioDAO.ai